临床和实验室研究年鉴

  • 国际标准期刊号: 2386-5180
  • 期刊 h 指数: 17
  • 期刊引用分数: 6.26
  • 期刊影响因子: 5.31
索引于
  • Genamics 期刊搜索
  • 中国知网(CNKI)
  • 引用因子
  • 研究期刊索引目录 (DRJI)
  • 普布隆斯
  • 欧洲酒吧
  • 谷歌学术
  • 夏尔巴罗密欧
  • 秘密搜索引擎实验室
分享此页面

抽象的

Evaluation of Four Tumor Markers (CEA, AFP, CA125 and CA19-9) on Sysmex HISCL- 5000 Immunoassay Analyzer

Sonu Bhatnagar, Ma Cecilia Fernandez Lim and Agustina Dominguez Abelardo

Background: Although great effort in standardization has been instituted worldwide, discrepancies among results from different immunoassay analyzers are still reported. Hence the evaluation of new assays has been advised before their implementation in the laboratory. We evaluated the assay performance of the Sysmex HISCL-5000 automated analyzer in measuring four tumor markers i.e. CEA, AFP, CA 125 and CA 19-9 and method comparison with ARCHITECT i2000SR immunoassay analyzer.

Method: The limit of detection, dilution linearity and imprecision performance of the four tumor marker assays were evaluated, and method comparison was done using 236 specimens collected from patients with respective cancers.

Results: The results on the limit of detection, linearity and imprecision were highly acceptable. Good correlation was found between the two methods compared for all the tumor markers studied (R=0.96 for CA125; R=0.98 for CEA; R=0.99 for AFP and R=0.57 for CA19-9).

Conclusion: In our study, HISCL-5000 immunoassay analyzer showed good analytical performance for the tested four tumor markers. Regardless of high correlations, Passing-Bablok regression indicated lower comparability between two immunoassays for CA 125 and CA19-9. Hence, it is of utmost importance for clinical laboratories to evaluate and do parallel testing before implementing any new assays.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证